

**Virginia Medicaid Preferred Drug List (PDL) Program:  
Annual Review of PDL Phase I and Review of New Drugs and Classes  
Pharmacy and Therapeutics Committee Meeting  
Wednesday, October 3, 2007  
10:00 a.m., 7<sup>th</sup> Floor Conference Rooms  
**DRAFT AGENDA****

**Welcome and Comments**

**Patrick Finnerty,  
DMAS Director**

**Comments**

**Randy Axelrod, M.D.,  
Chairman**

**Acceptance of Minutes From  
April 17, 2007 P&T Meeting**

**P&T Committee Members**

**Review of Draft Guidance Document for  
Generic Drug Policy\***

**P&T Committee Members**

**Drug Class Discussions**

**Generic Drug Watch**

**First Health Services  
Corporation**

**Review of Potential New Drug Classes**

- Hepatitis C Treatment Agents
- Growth Hormones

**P&T Committee Members**

**Review of New Drugs in PDL Phase II**

- Terbinafine Hydrochloride -- *Oral Antifungals for Onychomycosis*
- Cefdinir Capsule & Suspension – *Cephalosporins*
- Vyvanse<sup>®</sup> - *Antihyperkinesis/CNS Stimulants*

**P&T Committee Members**

**Phase I PDL Annual Review**

***Cardiac Medications***

- HMG CoA Reductase Inhibitors (Statins)
- Lipotropics Non-Statins: Fibric Acid
- Lipotropics Non-Statins: Niacin Derivatives
- Phosphodiesterase 5 Inhibitor for Pulmonary Arterial Hypertension
- Angiotensin Receptor Blockers (ARBs)
- Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)
- Beta Blockers
- Calcium Channel Blockers

***Central Nervous System***

- Benzodiazepine Sedative Hypnotics
- Other Sedative Hypnotics

***Gastrointestinal***

- Proton Pump Inhibitors (PPIs)
- Histamine 2 Receptor Antagonists (H-2RA)

***Genitourinary***

- Urinary Tract Antispasmodics

***Miscellaneous***

- Electrolyte Depleters
- Topical Immunomodulators

## **Phase I PDL Annual Review (continued)**

### ***Asthma and Allergy***

- Inhaled Corticosteroids
- Nasal Steroids
- Beta Adrenergics
- COPD- Anticholinergics
- Second Generation Antihistamines (LSAs)

### **Confidential Meeting**

**Confidential Meeting for P&T Committee Members, DMAS, and FHSC Pursuant to 42 U.S.C. § 1396r-8 to discuss pricing information**

### **Criteria Discussion of New Drug Classes\*\***

**P&T Committee Members**

### **Criteria Discussion of Phase II New Drugs\*\***

**P&T Committee Members**

### **Criteria Discussions for PDL Phase I Drug Classes\*\***

**P&T Committee Members**

### **Next Meeting**

**Randy Axelrod, M.D.,  
Chairman**

*\*Public comments will be accepted on Draft Guidance Document for Generic Drug Policy. The document may be found on the DMAS web site at the following link: [http://www.dmas.virginia.gov/pharm-p&t\\_committee.htm](http://www.dmas.virginia.gov/pharm-p&t_committee.htm) . **Written comments and requests to present on the Draft Guidance Document during the meeting must be submitted by COB Monday, September 24, 2007. Requests to present should include the name, title, and affiliation of the presenter.***

*\*\*Criteria discussions will be held for classes only if deemed PDL eligible by the P&T Committee during Drug Class Discussions*

**Oral presentations:** The P&T Committee in conjunction with the Department will be allocating time slots for interested parties to present scientific and clinical information on ***only*** the drug classes subject to PDL Phase I annual review and specific new drugs in PDL Phase II classes listed on the Agenda. All presentations must include newly published information (per guidelines below) that is clinical in nature and based on scientific material. The references used to authorize presentations must be within the following timeframes:

- PDL Phase I Annual Review – October 2006 to present
- New Drugs in PDL Phase II Drug Classes – March 2006 to present
- New Drug Classes (Hepatitis C and Growth Hormones) – September 2004 to present

No anecdotal accounts are to be given. Each speaker will be allocated no more than 3 minutes to present. The actual speakers will be decided by the Chairperson based on relevancy of the information. **Speakers must receive a confirmation number to verify the presentation is scheduled.**

If you are interested in providing specific clinical information to the Committee at the meeting, please submit an outline of discussion points, clinical references (within the stated guidelines above) and a written request to speak with the name/title of the presenter. Please send information to [pdlinput@dmas.virginia.gov](mailto:pdlinput@dmas.virginia.gov). **Information must be submitted by COB Wednesday, September 12, 2007 for Phase I classes and new drugs in Phase II classes. Information for new drug classes must be submitted by COB Monday, September 24, 2007.**

**Written information/comments:** The P&T Committee will also accept written comments for consideration. Please send statements to [pdlinput@dmas.virginia.gov](mailto:pdlinput@dmas.virginia.gov). **Comments must be submitted by COB Wednesday, September 12, 2007 for Phase I classes and new drugs in Phase II classes. Comments for new drug classes must be submitted by COB Monday, September 24, 2007.**